Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M98,286Revenue $M23,777Net Margin (%)23.0Altman Z-Score2.3
Enterprise Value $M119,525EPS $3.3Operating Margin %34.2Piotroski F-Score7
P/E(ttm)18.4Beneish M-Score-2.0Pre-tax Margin (%)29.6Higher ROA y-yY
Price/Book24.910-y EBITDA Growth Rate %--Quick Ratio1.3Cash flow > EarningsY
Price/Sales4.45-y EBITDA Growth Rate %-0.4Current Ratio1.5Lower Leverage y-yN
Price/Free Cash Flow14.3y-y EBITDA Growth Rate %117ROA % (ttm)12.7Higher Current Ratio y-yY
Dividend Yield %3.5PEG--ROE % (ttm)157Less Shares Outstanding y-yN
Payout Ratio %64.0Shares Outstanding M1,611ROIC % (ttm)31.5Gross Margin Increase y-yY

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVKen Fisher 2016-03-31 Reduce-0.02%$51.18 - $59.24
($55.77)
$ 61.009%Reduce -20.51%743,284
ABBVNWQ Managers 2015-12-31 Reduce-0.65%$48.27 - $64.13
($57.69)
$ 61.006%Reduce -50.59%754,413
ABBVFirst Eagle Investment 2015-12-31 Sold Out -0.14%$48.27 - $64.13
($57.69)
$ 61.006%Sold Out0
ABBVJoel Greenblatt 2015-12-31 Add0.08%$48.27 - $64.13
($57.69)
$ 61.006%Add 179.54%204,171
ABBVJohn Paulson 2015-12-31 Buy 0.05%$48.27 - $64.13
($57.69)
$ 61.006%New holding139,700
ABBVDavid Dreman 2015-12-31 Reduce-0.03%$48.27 - $64.13
($57.69)
$ 61.006%Reduce -15.80%26,267
ABBVKen Fisher 2015-12-31 Add$48.27 - $64.13
($57.64)
$ 61.006%Add 0.77%935,104
ABBVMario Gabelli 2015-12-31 Reduce$48.27 - $64.13
($57.69)
$ 61.006%Reduce -7.58%40,600
ABBVFirst Eagle Investment 2015-09-30 Add0.05%$52.5 - $71.23
($65.09)
$ 61.00-6%Add 55.71%1,056,150
ABBVJoel Greenblatt 2015-09-30 Add0.02%$52.5 - $71.23
($65.09)
$ 61.00-6%Add 117.34%73,037
ABBVDavid Dreman 2015-09-30 Add0.02%$52.5 - $71.23
($65.09)
$ 61.00-6%Add 10.27%31,197
ABBVKen Fisher 2015-09-30 Reduce-0.01%$52.5 - $71.23
($65.09)
$ 61.00-6%Reduce -7.82%927,959
ABBVMario Gabelli 2015-09-30 Reduce$52.5 - $71.23
($65.09)
$ 61.00-6%Reduce -5.65%43,930
ABBVDodge & Cox 2015-09-30 Reduce$52.5 - $71.23
($65.09)
$ 61.00-6%Reduce -2.92%33,255
ABBVNWQ Managers 2015-09-30 Reduce$52.5 - $71.23
($65.09)
$ 61.00-6%Reduce -3.59%1,526,806
ABBVJoel Greenblatt 2015-06-30 Reduce-0.23%$57.01 - $70.46
($65.18)
$ 61.00-6%Reduce -93.95%33,605
ABBVNWQ Managers 2015-06-30 Reduce-0.19%$57.01 - $70.46
($65.18)
$ 61.00-6%Reduce -13.88%1,583,682
ABBVDavid Dreman 2015-06-30 Add0.11%$57.01 - $70.46
($65.18)
$ 61.00-6%Add 193.03%28,292
ABBVFirst Eagle Investment 2015-06-30 Buy 0.11%$57.01 - $70.46
($65.18)
$ 61.00-6%New holding678,300
ABBVKen Fisher 2015-06-30 Reduce$57.01 - $70.46
($65.18)
$ 61.00-6%Reduce -0.40%1,006,679
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schumacher Laura JExecutive Vice President 2016-03-08Sell25,000$56.098.75view
RICHMOND TIMOTHY J.SVP, Human Resources 2016-03-01Sell12,866$55.0510.81view
SALEKI-GERHARDT AZITASVP, Operations 2016-02-29Sell1,776$55.3810.15view
HURWICH THOMAS A.VP, Controller 2016-02-29Sell1,444$55.2510.41view
GONZALEZ RICHARD AChairman of the Board and CEO 2015-07-29Sell40,021$71.24-14.37view
GONZALEZ RICHARD AChairman of the Board and CEO 2015-07-29Sell24,979$71.09-14.19view
HURWICH THOMAS A.VP, Controller 2015-05-19Sell6,200$66-7.58view
GONZALEZ RICHARD AChairman of the Board and CEO 2015-04-28Sell8,281$64.92-6.04view
GONZALEZ RICHARD AChairman of the Board and CEO 2015-04-28Sell64,232$64.84-5.92view
GONZALEZ RICHARD AChairman of the Board and CEO 2015-04-28Sell102,964$64.67-5.67view

Quarterly/Annual Reports about ABBV:

News about ABBV:

Articles On GuruFocus.com
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
A Cheap Dividend Aristocrat Yielding Over 4% Mar 02 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Gilead, Johnson & Johnson or Roche? Feb 11 2016 
Glenview's Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Health Care Investor Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? Nov 12 2015 
Companies Return 12-Month Record Amount to Shareholders Sep 25 2015 
Baxalta Vs. AbbVie: Biopharma Spin-Off Battle Aug 20 2015 
JNJ – Should It Be In Your Portfolio? Aug 19 2015 

More From Other Websites
ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Apr 29 2016
Worst may be over for embattled pharma Apr 29 2016
AbbVie (ABBV) Stock Price Target Hiked at Jefferies Apr 29 2016
Pharma stocks to bet on Apr 29 2016
AbbVie Gets European Medicines Agency's Positive Opinion For Its IMBRUVICA Apr 29 2016
AbbVie Doubles Down on M&A Apr 29 2016
AbbVie to Present at the Bank of America Merrill Lynch 2016 Global Health Care Conference Apr 29 2016
9:20 am AbbVie confirms European Medicines Agency issues 'positive opinion' for the use of Imbruvica... Apr 29 2016
European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib) as a... Apr 29 2016
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment... Apr 29 2016
AbbVie to Present at the Bank of America Merrill Lynch 2016 Global Health Care Conference Apr 29 2016
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment... Apr 29 2016
Biogen, AbbVie multiple sclerosis drug wins EU green light Apr 29 2016
Galapagos and AbbVie expand their cystic fibrosis collaboration Apr 29 2016
Galapagos and AbbVie expand their cystic fibrosis collaboration Apr 29 2016
[$$] Drugmakers Place Big Bets on Cancer Medicines Apr 28 2016
[$$] Abbott Agrees to Buy St. Jude in $25 Billion Deal Apr 28 2016
US STOCKS-Wall St sinks on BOJ fears, Icahn comments Apr 28 2016
[$$] Abbott Agrees to Buy St. Jude in $25 Billion Deal Apr 28 2016
Stemcentrx Sale to Return a Record $1.7 Billion for VC Firm Founders Fund Apr 28 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)